



# CytoSorbents™

Working to Save Lives Through Blood Purification

## CytoSorbents Establishes Swiss Subsidiary

MONMOUTH JUNCTION, N.J., May 6, 2016 – CytoSorbents Corporation (NASDAQ: [CTSO](#)), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that one of its operating subsidiaries, CytoSorbents Europe GmbH, has established a new wholly-owned subsidiary, CytoSorbents Switzerland GmbH.

Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, “Switzerland is an important market where CytoSorb® is helping physicians regain control of their unstable patients in the intensive care unit and during and after open heart surgery. CytoSorb® has the potential to work with or replace, in some cases, standard of care therapies to help control deadly inflammation and save lives. This new Swiss subsidiary will help facilitate direct sales, promote greater key opinion leader collaborations in the country, and ensure the timely delivery of CytoSorb® devices to patients in need.”

### **About CytoSorbents Corporation (NASDAQ: CTSO)**

CytoSorb® is approved in the European Union with distribution in 32 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorb® has been used safely in more than 11,000 human treatments to date.

CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's websites: <http://www.cytosorbents.com> and <http://www.cytosorb.com>

### **Forward-Looking Statements**

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking

statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 9, 2016, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

**[Please Click to Follow Us on Facebook and Twitter](#)**

**Cytosorbents Contact:**

Amy Vogel  
Investor Relations  
(732) 329-8885 ext. \*825  
[avogel@cytosorbents.com](mailto:avogel@cytosorbents.com)

**Investor Contact:**

Lee Roth  
The Ruth Group  
646-536-7012  
[lroth@theruthgroup.com](mailto:lroth@theruthgroup.com)

**Public Relations Contact:**

Christopher Hippolyte  
The Ruth Group  
646-536-7023  
[chippolyte@theruthgroup.com](mailto:chippolyte@theruthgroup.com)